Seagen, founded in 1998, is a seasoned player in the biotechnology sector, particularly focusing on oncology. Over the past 25 years, it has positioned itself as a transformative force in cancer care. The company's visionary slogan, "A global biotechnology company dedicated to developing revolutionary therapies with real impact," reflects its commitment to altering the landscape of cancer treatment.
Seagen's business model focuses on the research, development, and commercialization of groundbreaking cancer therapies, serving patients with both solid tumors and blood-related cancers. The company is recognized for its pioneering work in developing antibody-drug conjugates, representing a significant advancement in targeted cancer therapeutics.
In a recent funding round, Seagen secured a $12.92M Post IPO Equity investment from Polar Asset Management Partners on 01 December 2023. This investment signifies strong investor confidence in Seagen's potential to continue making strides in the biotech field, underlining its role in advancing innovative cancer treatments.
